Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 12, 2026Journal of Cancer Research and PracticeOpen Access

Combination Therapy of Anti-PD-1 Immunotherapy and Taxanes in Relapsed and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Real-world Single-center Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

TLTing-Wen LiuNSNai-Wen SuYCY-F Chang

Discussion

Loading...

Member takes

Overview

Retrospective study evaluates outcomes of PD-1 inhibitor and taxane therapy in metastatic head and neck cancer patients, suggesting positive efficacy.

Key Points

  • To assess the efficacy and safety of a chemo-immunotherapy regimen combining PD-1 inhibitors and taxanes in R/M-HNSCC patients.
  • Retrospective analysis of 24 patients' medical charts
  • Patients aged ≥18 with unresectable R/M-HNSCC
  • All patients received PD-1 inhibitor and taxane therapy
  • Primary endpoints were progression-free survival and objective response rate
  • Secondary endpoints included overall survival and toxicity assessment.
  • Objective response rate was 50%
  • Disease control rate was 66.7%
  • Median progression-free survival was 6.4 months
  • Median overall survival was 11.6 months
  • Common adverse events included anemia (58.3%) and hypothyroidism (29.2%).

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69db375f4fe01fead37c5580https://doi.org/10.4103/ejcrp.ejcrp-d-25-00043
View Full Paper
Ask AI
Bookmark
Share